Will I remember my ketamine session?

Most patients remember the broad shape of the session but not every specific detail. Patchy memory of the experience itself is normal and expected. You will remember being cared for, the room, and your check-ins with the CRNA, but the imagery and inner content during the dissociative window may be hard to recall precisely. That fading is part of how ketamine works on the NMDA system, and it does not predict any longer-term effect on memory.

Why do I feel foggy the day after?

Mild fog the rest of the day and sometimes into the next morning is a known effect. Sleep, hydration, light food, and a quiet evening usually resolve it. If foggy thinking lasts more than 24 to 48 hours after a session, or it gets worse across a series rather than easing, tell your prescriber and our team. That pattern is uncommon and worth reviewing.

Is it safe to do ketamine if I'm worried about early dementia?

Cognitive concerns deserve careful screening. Talk to your prescribing provider and, if you have one, your neurologist before considering ketamine. We will review your history during the consultation and may ask for input from your treating clinicians. We are not the right setting for every patient, and we will tell you honestly if we think the risk-benefit picture is unclear in your case.

Will repeated sessions add up to memory damage?

Cumulative memory damage from a clinical series has not been demonstrated in the published literature on therapeutic dosing. Studies of repeated infusions for treatment-resistant depression have followed patients across multiple sessions without finding persistent cognitive decline. We track how you feel between sessions and across the series, and we slow down or pause if anything changes. Recreational frequency and dose levels are a separate question with different risks.

Ketamine and Memory: Short-Term Fog, Long-Term Research, and What's Actually Normal

Q: Does ketamine cause long-term memory loss?

At therapeutic doses used for treatment-resistant depression and chronic pain, the available research has not shown persistent memory loss or cognitive decline. Diamond and colleagues, writing in the Journal of Psychopharmacology in 2014, followed patients through repeated IV infusions and did not find lasting impairment in tested cognitive domains. Recreational misuse at much higher doses and frequencies is a different picture and is not what we do clinically.

The two questions patients actually ask

Almost every patient who calls about ketamine asks some version of two questions about memory. The first is small and immediate: will I remember the session itself? The second is bigger and quieter: am I doing something to my brain that will catch up with me later?

Both questions deserve a direct answer. The short version is that some patchy memory of the session is normal and expected, and the long-term cognitive research on therapeutic-dose ketamine is reassuring. Neither answer is a guarantee, and we are not in the business of overselling. Ketamine is FDA-approved as an anesthetic; its use for depression, PTSD, and chronic pain is off-label, and that off-label framing applies to the cognitive questions too—most of what we know comes from clinical trials in those off-label conditions.

What follows is the version we give patients in the consult room, in the order it usually comes up.

Acute memory effects: what happens during and right after a session

During a ketamine infusion, you enter a dissociative state. Time loosens. Sensations soften. Internal imagery often becomes vivid. Most patients describe the experience as dreamlike, and dreams are exactly the right comparison for what memory does in that window. You will likely remember that things happened more clearly than you remember exactly what happened.

This is by design, not by accident. Ketamine works at the NMDA receptor, the same receptor system that helps the hippocampus consolidate new short-term experiences into stable long-term memories. Temporarily quieting that system is part of how the drug produces its dissociative and antidepressant effects. The trade-off is that detailed encoding of session content is reduced while the medicine is active.

The fog does not switch off the moment the infusion stops. Most patients feel mostly themselves within thirty to ninety minutes, but mild slowness, soft thinking, and patchy recall can extend through the rest of the day and sometimes into the next morning. This is also why we have firm discharge criteria and why you cannot drive yourself home. The memory and reaction-time effects overlap with the legal definition of impairment for several hours.

The dissociation–memory link (and why CADSS scores matter)

The most-used measurement tool in ketamine research is the Clinician-Administered Dissociative States Scale, or CADSS, developed by Bremner and colleagues and published in the Journal of Traumatic Stress in 1998. The scale was originally built to study dissociation in trauma populations, and it captures three broad domains: amnesia, depersonalization, and derealization.

That first domain, amnesia, is part of why the scale shows up in nearly every modern ketamine study. The dissociation that ketamine produces and the patchy memory that comes with it are clinically linked. They rise together during the infusion, and they fade together as the drug clears. Trials that report CADSS scores almost always show a sharp peak during dosing followed by a return toward baseline within an hour or two.

For more on the dissociative experience itself—what it feels like and how to work with it—our explainer on understanding dissociation during ketamine goes deeper. The point here is narrower: in the supervised, low-to-moderate doses used clinically, the same mechanism that produces dissociation also produces the expected, transient memory blur. They are two readings on the same dial.

What the longer-term studies show

This is where most patients want a real answer rather than reassurance. The honest version is that the research on repeated therapeutic-dose ketamine has not shown the kind of long-term cognitive damage that people often fear.

Diamond and colleagues, writing in the Journal of Psychopharmacology in 2014, followed patients receiving repeated IV ketamine infusions for treatment-resistant depression and tested cognitive performance across the series. They did not find persistent impairment in the tested domains. That finding has been broadly consistent with later clinical work in depression, PTSD, and chronic pain populations: short-term effects during the dosing window, a return to baseline between sessions, and no signal of cumulative cognitive decline at the doses used clinically.

The FDA Spravato (esketamine) prescribing information, updated in 2024, tells a similar story from the regulatory side. Acute cognitive effects, including dissociation and short-term memory disturbance during the post-dose monitoring window, are listed plainly. Chronic cognitive effects studied across the registration trials did not show persistent decline. That is a meaningful data point, because Spravato trials enrolled patients who received repeated dosing for months at a time.

For a broader walk-through of the brain-effects literature, our overview of what the ketamine brain research actually shows covers neuroplasticity, BDNF, and structural imaging studies in more detail. The narrower point for memory is this: research suggests that, at therapeutic doses given in a supervised clinical setting, repeated infusions have not been linked to lasting cognitive harm in the tested populations.

Recreational misuse vs. therapeutic dosing—a critical distinction

None of the reassurance above transfers cleanly to recreational use, and we have to say this part out loud. Heavy, frequent recreational ketamine use—daily insufflation at multi-gram amounts, sustained over months or years—is associated with a different and worse profile. Studies of heavy users have reported measurable cognitive deficits, particularly in working memory, and a pattern of urinary tract injury that is well documented in the urology literature.

The doses, frequencies, routes, and supervision levels are not comparable. A single clinical IV infusion delivers a controlled, weight-based dose with continuous monitoring, sterile preparation, and a planned end. A heavy recreational pattern stacks unmonitored doses on top of each other across days and weeks, often combined with other substances.

When patients ask whether ketamine is safe long-term, this is the distinction that matters. The therapeutic and recreational pictures are not the same conversation. We treat therapeutic safety as a clinical-monitoring question, not a generalization from internet stories about heavy use.

Who should be more cautious

Some patients deserve a slower, more careful look before starting. Older adults with baseline memory concerns, anyone with a documented mild cognitive impairment workup in progress, and patients with a family history of early-onset dementia all warrant extra screening. We are not refusing those patients reflexively. We are saying that the risk-benefit conversation is different and that a neurology consult or a clear word from the prescribing psychiatrist often belongs in the file.

Other groups that prompt extra caution include patients with active heavy alcohol use, patients on medications with significant cognitive side effects of their own, and patients recovering from a recent concussion. In each case, the question is not whether ketamine is dangerous in the abstract. It is whether we can tell the difference between a baseline cognitive signal and a treatment effect once the series is underway. Clear baselines make that easier.

If any of the above describes you, please raise it during the consultation. We would rather have a longer first conversation than an unclear third session.

What we test for and what we monitor across a series

Inside the clinic, every infusion runs under anesthesia-level monitoring with continuous pulse oximetry, blood pressure, and heart rate tracking. Marla Peterson, CRNA, oversees every infusion and is on-site throughout the session. The same vigilance that exists for cardiovascular safety also covers cognitive and behavioral signals. If a patient is unusually slow to clear the dissociative window, more confused than expected on emergence, or visibly different from their prior sessions, that gets noted and flagged before discharge.

Across a series, we track how you feel between sessions. We ask about fog the next day, sleep quality the following nights, and whether your usual mental sharpness returns within the expected window. Patterns matter more than single sessions. A one-off groggy morning is normal. A trend of worsening fog across three or four sessions is worth pausing for.

Cost is part of the honest conversation too. Sessions at our clinic are $475 each, and the off-label use of ketamine for psychiatric and pain conditions is typically not covered by insurance. We would rather you know that going in than learn it after the fact.

When to flag a cognitive change to your prescriber

A short list, in plain language. Tell your prescriber, your neurologist if you have one, and our team if any of the following show up:

Fog or slowness lasting more than 24 to 48 hours after a session, or worsening across the series rather than easing.
New word-finding trouble, names you should know going blank, or repeated lost-thought episodes that persist between sessions.
Family or close partners noticing a change you have not noticed yourself. Outside observers often catch drift earlier than the person experiencing it.
Disorientation about time, place, or recent events that does not resolve within hours of the infusion ending.
Any cognitive change that feels qualitatively different from the expected, transient session-day fog described above.

None of these means stop everything immediately on your own. They mean call us and call your prescribing provider so the team can decide together whether to pause, slow down, or continue. Never stop or change medications without consulting your prescribing provider. Our job is to make that loop fast, not to make decisions in isolation.

Most patients will not see anything on this list. The expected pattern is mild fog the day of the session, a normal next morning, and a return to baseline. Knowing what is normal makes it easier to spot what is not.